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Abstract 
Introduction: Sleep disturbances are common non-motor symptoms in Parkinson’s disease 
(PD). Experimental studies suggest involvement of the serotonergic system in the regulation 
of sleep and arousal. Using [
11
C]DASB positron emission tomography, a marker of serotonin 
transporter availability, we investigated whether sleep dysfunction is associated with 
serotonergic dysfunction in PD.  
Methods: We studied 14 PD patients with sleep dysfunction, 14 PD without sleep 
dysfunction, and 12 healthy controls. Groups were matched for age, disease duration, severity 
of motor symptoms, daily intake of levodopa equivalent units, body-mass-index, depression 
and fatigue. [
11
C]DASB non-displaceable binding potential (BPND) was calculated for regions 
with a role in the regulation of sleep and arousal.  
Results: [
11
C]DASB BPND was reduced by 32-49% in PD patients with sleep dysfunction, 
and 14-25% in PD without sleep dysfunction, compared to healthy controls. PD patients with 
sleep dysfunction had lower [
11
C]DASB BPND in caudate (P<0.01), putamen (P<0.001), 
ventral striatum (P<0.001), thalamus (P<0.05), hypothalamus (P<0.001) and raphe nuclei 
(P<0.01), compared to PD without sleep dysfunction. Higher severity of sleep symptoms 
(assessed with Parkinson Disease Sleep Scale) correlated with lower [
11
C]DASB binding in 
caudate (r=0.77; P<0.001), putamen (r=0.84; P<0.001), ventral striatum (r=0.86; P<0.001), 
thalamus (r=0.79; P<0.001), hypothalamus (r=0.90; P<0.001) and raphe nuclei (r=0.83; 
P<0.001).  
Conclusions: Our findings demonstrate that sleep dysfunction in PD is associated with 
reduced serotonergic function in the midbrain raphe, basal ganglia and hypothalamus. 
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Strategies to increase serotonin levels in the brain could be a promising approach to treat 
sleep dysfunction in PD, and may also have relevance in other neurodegenerative disorders. 
Keywords: Parkinson’s disease; Sleep disturbances; Serotonin; DASB; PET 
Abbreviations: 5-HT = Hydroxytryptophan (serotonin); BPND = Non-Displaceable Binding 
Potential; DASB = [N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine]; EDS = 
Excessive Daytime Somnolence; ROI = Region Of Interest; RBD = Rapid Eye Movement 
Behaviours Disorders; SERT = Serotonin Transporter 
 
1. Introduction  
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterised by the 
cardinal motor symptoms of bradykinesia, rigidity and tremor, and a range of frequent non-
motor symptoms such as sleep disturbances, depression and chronic fatigue. Sleep 
disturbances are estimated to affect between 15-96% of patients with PD, constituting a 
significant source of complaint and affecting quality of life 
1, 2
. Sleep disturbances in PD are 
typically divided to insomnia, parasomnias including rapid eye movement (REM) behaviours 
disorders (RBD), excessive daytime sleepiness (EDS) and drug induced sleep dysfunctions 
3
. 
Neurochemical systems including acetylcholine, noradrenaline, dopamine, histamine, 
orexin/hypocretin and serotonin interact to regulate the sleep-wake cycle 
4
. Mechanisms 
underlying the pathophysiology, and high prevalence, of sleep dysfunction in PD remain 
poorly understood. The occurrence of sleep dysfunction predating motor symptoms in PD 
raises the possibility that Lewy body pathology could play a role. Pre-clinical Parkinson’s 
stages reflect the spread of Lewy body pathology to the raphe nucleus 
5
, the primary source 
of serotonin (5-HT) neurotransmitter. Serotonergic projections innervate brain regions 
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involved in the regulation of sleep, wakefulness and arousal including the forebrain, 
hypothalamus, thalamus, basal ganglia and preoptic area 
6
.  
Post-mortem studies revealed up to 50% loss of serotonergic neurons in the brains of patients 
with PD 
7
. Biochemical studies confirmed these findings demonstrating decreased levels of 
serotonin transporter (SERT) protein in striatal and extra-striatal areas 
8, 9
. Positron emission 
tomography (PET) molecular imaging studies measuring SERT availability have revealed 
reductions of striatal and extra-striatal 5-HT including raphe nuclei, thalamus and 
hypothalamus 
10-12
. Furthermore, PET studies have linked serotonergic dysfunction with the 
development of dyskinesias 
13
, tremor 
14
, depression 
15
, apathy and anxiety 
16
, fatigue 
17
, 
weight loss 
18
 and visual hallucinations 
19
 in PD.  Therefore, there is compelling evidence 
from preclinical, post-mortem and human imaging studies for the role of serotonergic 
dysfunction in PD. 
The serotonergic system plays a critical role in the sleep-wake cycle and its dysfunction could 
have relevance to the development of sleep disturbances in PD. Animal studies have 
demonstrated that lesions in the raphe nucleus result in reduced sleep which is associated 
with lower levels of serotonin 
20
. Changes in raphe nuclei following sleep deprivation 
included increases in neuronal size, increased firing during wake and downregulation of 5-
HT receptors 
21
. Preclinical PET studies with [
11
C]DASB demonstrated decreases in SERT 
binding in rats deprived of sleep 
21
. Furthermore, PET studies in patients with PD have 
revealed reductions in SERT availability in key brain regions involved in the regulation of 
sleep and wakefulness 
12
.  
In this study, we hypothesized that PD patients with sleep dysfunction, as clinically identified 
using the original version of Parkinson Disease Sleep Scale (PDSS) 
22
, would show reduced 
serotonergic function in brain areas modulating sleep and arousal. The PDSS is widely 
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validated and recommended by the MDS task force for clinical assessment of a range of sleep 
disorders and severity in PD 
23
. We sought to investigate this in vivo using [
11
C]DASB PET 
molecular imaging, as a marker of SERT availability. 
2. Material and methods  
2.1 Participants 
Patient selection was carried out from a cohort of 56 patients with a clinical diagnosis of 
idiopathic PD (Figure 1), according to the UK Brain Bank criteria, recruited from specialist 
Movement Disorders clinics at King’s College Hospital. Based on study selection criteria, 
Parkinson’s patients with dementia [Mini-Mental State Examination (MMSE) <24], 
depression [Hamilton Rating Scale for Depression (HRSD) >13 and Beck Depression 
Inventory-II (BDI-II) >17], fatigue [Non-Motor Symptom Scale (NMSS) fatigue sub-item], 
and abnormal weight gain or loss [Body Mass Index (BMI) change >1 unit in the last 12 
months] were excluded from the study. Twelve age-matched healthy individuals, with no 
history of neurological or psychiatric disorders and no family history of PD, served as the 
control group (Table 1). 
Twenty-eight Parkinson’s patients, who met the selection criteria, were divided into two 
groups according to the presence (n=14) or absence (n=14) of sleep dysfunction (Figure 1; 
Table 1). We screened for sleep dysfunction based on a three-layer approach: (a) Complaint 
by the patient or carer; (b) Unified PD Rating Scale (UPDRS) Part-I, Item 1.7 (Sleep 
dysfunction): >2 Mild, Moderate or Severe Sleep dysfunction as opposed to ‘0’ no sleep 
dysfunction. Patients who scored ‘1’ slight sleep dysfunction were excluded; and (c) by using 
the PDSS with a validated cut-off of <82 to define sleep dysfunction in patients with 
Parkinson Disease 
24
. The PDSS, cut-off of scores <82, was used for the final classification of 
the presence of sleep dysfunction.  
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PDSS was also used to quantify severity of sleep dysfunction, and for interrogating 
correlations with the PET data. The PDSS is a validated 15-item scale measuring commonly 
reported symptoms associated with sleep dysfunction 
22
. Each item is rated from worst (0) to 
best state (10); the total score is calculated as the sum of the item scores with a maximum 
score of 150. Lower PDSS scores imply higher burden of sleep symptoms. The PD groups 
were matched for age, disease duration, severity of motor symptoms [Unified Parkinson’s 
Disease Rating Scale part-III (UPDRS-III) and Hoehn & Yahr (H&Y) scale], daily intake of 
levodopa equivalent units, body-mass-index, and depression (BDI-II and HRSD) and fatigue 
levels (NMSS) (Table 1). None of the subjects had dyskinesias or were receiving medication 
with known action on the serotonergic system, or medication that affects the sleep-wake cycle 
including trazodone, melatonin, or stimulants. 
All participants screened successfully to undertake PET and magnetic resonance imaging 
(MRI) scanning under standard criteria (http://www.mrisafety.com; 
https://www.gov.uk/government/publications/arsac-notes-for-guidance). Written informed 
consent was obtained from all study participants in accordance with the Declaration of 
Helsinki. The study was approved by the institutional review boards and the research ethics 
committee. Permission to administer [
11
C]DASB was obtained from the Administration of 
Radioactive Substances Advisory Committee, UK. 
2.2 Scanning procedures 
Participants were scanned using a GE Discovery RX PET/CT scanner. The mean injected 
dose for [
11
C]DASB was 400MBq and scanning began 30s before tracer infusion as an 
intravenous bolus, generating 28 time frames of tissue data over 90 min. Subjects were 
positioned supine with their transaxial planes parallel to the line intersecting the anterior-
posterior commissure line. Head position was maintained with the help of individualized 
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foam holders and monitored by video. Subjects were scanned at rest in a quiet room with low 
light. Smoking and consumption of alcohol, coffee and other caffeinated beverages were not 
allowed for 12 hours before scanning. Eating and drinking were not allowed for 8 hours 
before PET scanning. All PD patients were scanned OFF medication and following an 
overnight withdraw of their normal medications. 
MRI was performed using a clinical 1.5-Tesla MRI system (Siemens MAGNETOM Avanto) 
for the purposes of PET image co-registration and to facilitate localising the regions of 
interest (ROIs). The MRI protocol included volumetric T1 sequences (coronal and axial T1-
spin echo: TR=635ms, TE=17ms, 5mm slice thickness; T1 volumetric MPRAGE 
(TR=1900ms, TE=3.53ms, TI=1100ms, Flip angle 15, 1mm isotropic voxels), and T2-
weighted sequences (Axial T2-spin echo: TR=4540ms, TE=97ms, 5mm slice thickness; 
Axial FLAIR: TR=9000ms, TE=114ms, TI=2500ms, 5mm slice thickness). 
2.3 [
11
C]DASB PET analysis  
Individual PET frames were corrected for head motion using frame-by-frame realignment 
using a frame with high signal-to-noise ratio as reference. Summed dynamic [
11
C]DASB 
images were created from the entire series of uptake image volumes. Parametric images of 
[
11
C]DASB distribution volume ratios (DVR) were generated using the Logan reference 
model with reference region for non-specific tracer-binding signal in the posterior cerebellar 
grey matter cortex avoiding inclusion of the vermis 
25
. Regional concentrations of 
radioactivity (kBq/ml) were obtained from the full dynamic scan and decay-corrected time-
activity curves (TACs) were computed. PET images were anatomically co-registered and 
resliced to the corresponding T1-weighted MRI using the mutual information registration 
algorithm in the statistical parametric mapping (SPM) software package (Version 12).  
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Manual delineation of ROIs was performed on co-registered MRI and PET using ANALYZE 
medical imaging software (version 12, Mayo Foundation). ROIs were manually defined on 
both hemispheres for the caudate, putamen, ventral striatum, amygdala, thalamus, 
hypothalamus, globus pallidus, raphe nucleus, anterior cingulate cortex, posterior cingulate 
cortex, prefrontal cortex and insula. The binding potential of the specially bound radioligand 
relative to the non-displaceable radioligand (BPND) in the tissue was calculated as DVR-1 
26
. 
Since changes in BPND could be associated with degeneration or volumetric loss, we 
confirmed there were no differences in grey matter volumes on individual subjects MRIs 
between groups of PD patients with and without sleep disturbances and healthy controls; 
therefore, partial volume correction was not applied.  
2.4 Statistical analysis 
Statistical analysis and graph illustration were performed with SPSS (version 20 Chicago, 
Illinois, USA) and GraphPad Prism (version 6.0) respectively. For all variables, variance 
homogeneity and Gaussianity were tested with Barrlett and Kolmogorov-Smirnov tests, and 
we proceeded with parametric tests as our PET and clinical data were normally distributed. 
Regional [
11
C]DASB BPND among healthy controls, patients with PD with and without sleep 
dysfunction were compared using one-way ANOVA followed by Brown-Forsythe and 
Barrlett’s test. P values for each variable were calculated following Bonferroni multiple-
comparisons test. When ANOVA P values were significant, univariate comparisons and p 
values were calculated with Bonferroni post-hoc tests. Effect size was measured with 
Cohen’s d. We interrogated correlations between PET and clinical data using Pearson’s r 
correlation coefficient and we applied the Benjamini-Hochberg multiple-comparisons test to 
reduce false discovery rate; we set the false discovery rate cut-off at 0.05. All data are 
presented as mean ± standard deviation (SD). The α level was set at P<0.05, corrected for 
multiple comparisons.  
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3. Results  
Clinical measures between the two groups of patients with PD revealed no significant 
differences in age (P>0.10; r=0.12), MMSE scores (P>0.10; r =0.48), UPDRS-III scores 
(P>0.10; r=-0.20), daily intake of levodopa equivalent units (P>0.10; r=0.005), body-mass-
index scores (P>0.10; r=0.069), HRSD scores (P>0.10; r=-0.12) and BDI-II scores (P>0.10; 
r=-0.18) (Table 1). 
3.1 Regional [
11
C]DASB binding  
Mean [
11
C]DASB BPND values in ROIs were decreased by 14-25% in PD patients without 
sleep dysfunction and by 32-49% in Parkinson’s patients with sleep dysfunction, compared to 
healthy controls (Table 2). Parkinson’s patients with sleep dysfunction had decreased 
[
11
C]DASB BPND values, after correction for multiple comparisons, in the caudate (P=0.004; 
effect size d=1.33), putamen (P<0.001; effect size d=2.32), ventral striatum (P<0.001; effect 
size d=1.99), thalamus (P=0.017; effect size d=1.22), hypothalamus (P<0.001; effect size 
d=2.34) and raphe nuclei (P=0.009; effect size d=1.27) compared to Parkinson’s patients 
without sleep dysfunction (Table 2, Figures 2 and 3). While decreased [
11
C]DASB BPND was 
observed in the anterior and posterior cingulate and the insula between patients with PD and 
healthy controls, there were no differences in [
11
C]DASB BPND between Parkinson’s patients 
with and without sleep dysfunction in these areas. The prefrontal cortex, globus pallidus and 
amygdala showed no difference between group means as determined by ANOVA analysis 
(Table 2; Figure 2). There were no volumetric differences in any regions of interest between 
the groups of patients with PD and healthy controls (P>0.10) (Supplemental Data: Table e-1).   
3.2 Correlations 
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Lower individual PDSS scores, implying higher burden of sleep symptoms, correlated with 
lower [
11
C]DASB BPND values in the caudate (P<0.001; r=0.77), putamen (P<0.001; r=0.84), 
ventral striatum (P<0.001; r=0.86), thalamus (P<0.001; r=0.79), hypothalamus (P<0.001; 
r=0.90) and raphe nuclei (P<0.001;  r=0.83) in all 28 patients with PD (Figure 4).  
4. Discussion  
Our findings demonstrate that sleep dysfunction in PD is associated with reduced 
serotonergic function in the midbrain raphe, basal ganglia and hypothalamus. Using a 
[
11
C]DASB PET region of interest analytical approach, we found that SERT binding was 
decreased in the dorsal (caudate and putamen) and ventral striatum, thalamus, hypothalamus 
and raphe nuclei of Parkinson’s patients with sleep dysfunction compared to patients without 
sleep dysfunction. Furthermore, higher burden of sleep symptoms correlated with reduced 
SERT binding in the caudate, putamen, ventral striatum, thalamus, hypothalamus and raphe 
nuclei. These are key brain regions involved in the mechanisms regulating sleep, supporting 
the role of serotonergic dysfunction in the pathophysiology of sleep disorders in PD.  
Our results translate, into humans, preclinical findings highlighting the role of serotonergic 
dysfunction in the development of sleep disturbances. Neuronal activity in the basal ganglia 
is modulated by serotonin and dopamine during wakefulness and REM sleep 
27
. Preclinical 
studies showed that lesions within the basal ganglia led to alterations in the regulation of the 
sleep-wake cycle 
28, 29
. The dorsal striatum (caudate and putamen) enhances wakefulness, 
while the nucleus accumbens promotes sleep, and selective lesions in the external globus 
pallidus increase total wakefulness 
29
. Furthermore, 5-HT receptors in the caudate, putamen 
and nucleus accumbens are thought to play a role in circadian rhythms 
27
. In the thalamus, 5-
HT2 receptors are postulated to modulate both the excitation of the reticular nucleus leading 
to single-spike activity and waking, and the oscillatory activity of the reticular nucleus; 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
11 
 
implicating the thalamus in mechanisms for the arousing effects of serotonin 
30
. In animal 
studies, lesions in the raphe nucleus resulted in decreased sleep which was associated with 
lower levels of serotonin 
20
. Thus, findings of decreased SERT binding in the raphe, striatum 
and thalamus in PD patients with sleep dysfunction supports their role in mechanisms 
modulating the sleep-wake cycle. Due to the selectively, and differential expression, of 5-HT 
receptor subtypes throughout the brain; serotonergic stimulation yields complex effects on 
the sleep-switch, exerting both sleep incompatible and sleep promoting effects 
31-33
. 
Therefore, alterations in the serotoninergic system can lead to changes in sleep architecture 
and quality of sleep. Use of novel PET tracers to image and quantify the different 5-HT 
receptors subtypes in Parkinson’s patients with sleep dysfunction would help to further 
elucidate underlying mechanisms.  
Here, we report highest reductions in SERT binding in the hypothalamus in Parkinson’s 
patients with sleep dysfunction. The hypothalamus plays a central role in the regulation of 
sleep and circadian rhythms, and receives serotonergic projections from the raphe nucleus 
4
. 
The posterior tuberomammillary nuclei and lateral hypothalamus also modulate the sleep-
switch, acting predominantly to promote wakefulness 
34
. Involvement of the hypothalamus 
and raphe nucleus in PD sleep dysfunction is consistent with involvement of Lewy body and 
neurite depositions which occurs early in the disease 
5
. Lewy body pathology has been 
reported in hypothalamic orexin neurons (hypocretin area) 
35, 36
. Therefore, Lewy body 
pathology in the hypothalamus could result in loss of orexin neurons, which also interacts 
with dopaminergic networks of the hypothalamus and is thought to function as an external 
regulator of the flip-flop switch promoting wakefulness 
37
. Post-mortem studies have revealed 
loss of hypocretin neurons in PD brains and reduced levels of orexin in the cerebrospinal 
fluid (CSF), associated with sleep disorders, in patients with PD; implicating orexin neuronal 
loss and impaired orexin neurotransmission in PD pathophysiology 
35, 38
. Further studies are 
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required to fully understand regional loss of serotonin, as well as interaction with other 
regulators of sleep, in mechanisms underlying specific sleep disturbances in PD. 
Recently, non-motor endophenotypes of PD including the Park sleep phenotype have been 
described 
39
. Sleep disorders in PD are heterogeneous and complex, likely involving multiple 
neurotransmitter systems; thus, differentiating underlying pathophysiology of specific sleep 
phenotypes is challenging. A PET study with [
11
C]DASB found no association between 
severity of sleep disordered breathing and SERT binding 
40
. Loss of striatal [
123
I]FP-CIT has 
been associated with severity of EDS, suggesting daytime sleepiness is associated with 
dopaminergic nigrostriatal degeneration 
41
. A [
11
C]DASB PET study showed no differences 
in raphe nucleus and striatal SERT binding in patients with and without RBD symptoms 
42
. In 
RBD, degeneration of cholinergic neurons in the basal forebrain and brainstem, and loss of 
noradrenergic neurons in the locus coeruleus played a more prominent role than serotonergic 
dysfunction 
42
. Furthermore, a [
123
I]FP-CIT single-photon emission computed tomography 
(SPECT), study in idiopathic RBD patients showed no difference in brainstem and thalamic 
binding, but significant reductions in the basal ganglia; leading the authors to conclude that 
the serotonergic system is not directly involved in RBD pathogenesis 
43
. We provide evidence 
to suggest that serotonergic dysfunction is associated with sleep fragmentation, including 
sleep maintenance, nocturnal motor symptoms, nocturnal hallucinations and nocturia, as 
measured with the PDSS 
22
. Difficulty in maintaining sleep is often accompanied by a 
decrease in total sleep time and an increase in the number of awakenings during sleep and 
wakefulness after sleep onset. Serotoninergic dysfunction has previously been implicated to 
play a role in motor symptoms in PD 
13, 14
, therefore could contribute to development of 
nocturnal motor symptoms. Taken our results together with previous studies, it’s plausible 
that the development of nocturnal sleep disturbances is influenced by serotonergic 
dysfunction, whereas cholinergic, noradrenergic and dopaminergic pathology may underlie 
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the pathophysiology of RBD and EDS. However, future larger studies assessing correlations 
between serotonergic function and subsets of the PDSS, in combination with other 
neurotransmitter systems, are required to highlight which specific aspect of sleep-wake 
disturbances are associated with serotonergic dysfunction.  
To reduce the effects of possible confounding factors known to affect SERT binding, the two 
groups of patients with PD were carefully matched for age, disease duration, motor and non-
motor symptom burden, and levodopa treatment intake. Furthermore, patients with fatigue, 
dementia, depression and abnormal weight gain or loss were excluded to reduce effects of 
known confounding factors of [
11
C]DASB binding and sleep. However, co-morbid non-motor 
and cognitive factors could predispose, exacerbate or follow sleep dysfunction in PD; these 
factors should be considered when interrupting the results. In order to investigate the role of 
serotonin dysregulating contributing to the pathophysiology of sleep disturbances in PD, and 
to limit the effects of possible confounding factors, the PD cohort studied was relatively 
homogenous. Therefore, larger studies in a more heterogeneous population of patients with 
PD are required to further understand the wider clinical application of these findings. Here, 
we defined the presence of sleep disturbances using the validated Parkinson’s disease sleep 
scale. Further studies using specific sleep scales, and sleep electroencephalogram (EEG), are 
required to further investigate the role of serotonergic dysfunction in the development of 
specific types of sleep disturbances in patients with PD. 
Sleep disturbances are highly prevalent among other neurodegenerative diseases including 
Alzheimer’s disease and Lewy body dementia and Huntington’s disease. Recent studies have 
highlighted the role of the glymphatic system in the removal of potentially neurotoxic protein 
waste, which accumulates during wakefulness, from the brain at a highest rate during sleep 
44
. 
Dysregulation of the glymphatic system, potentially due to sleep dysfunction, could result in 
abnormal accumulation of protein aggregates such as alpha-synuclein and beta-amyloid 
45
. 
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Therefore, sleep dysfunction may not only be a side effect, but could contribute to a protein 
deposition and neurodegeneration. Alterations in the neurotransmitter systems could play a 
role in driving sleep dysfunction, subsequently contributing to dysregulation of the 
glymphatic system and the abnormal accumulation of protein aggregates underlying disease 
pathology. Studies investigating the involvement of the serotonergic system across 
neurodegenerative disorders could highlight if similar mechanisms underlie pathophysiology 
of sleep disturbances. Therapeutic strategies targeting serotonergic function may provide 
novel interventions to alleviate sleep disturbances with possible implications for disease 
pathology. 
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Figure 1 Summary flow-chat depicting the inclusion criteria and selection process of 
Parkinson’s patients with and without sleep dysfunction. PD = Parkinson’s disease; PDSS = 
Parkinson’s disease Sleep Scale; UPDRS-III = Unified Parkinson’s Disease Rating Scale 
part-III; H&Y = Hoehn & Yahr; BDI-II = Beck Depression Inventory-II; HRSD = Hamilton 
Rating Scale for Depression; MMSE = Mini Mental State Examination.   
Figure 2 Regional [
11
C]DASB BPND decreases in groups of Parkinson’s patients with and 
without sleep dysfunction. Column bar graphs showing mean [
11
C]DASB non-displaceable 
binding potential (BPND) in brain regions between Parkinson’s patients with and without sleep 
disturbances and healthy controls. Error bars represent mean ± SD. * P <0.05; ** P <0.001; 
*** P <0.001. All P values are Bonferroni corrected for multiple comparisons. 
Figure 3 Loss of [
11
C]DASB BPND in Parkinson’s patients with sleep dysfunction compared 
to patients without sleep dysfunction and healthy controls. [
11
C]DASB PET images co-
registered and fused with 1.5-Tesla MRI images showing basal ganglia and brain stem 
regions in healthy controls (64 year old female; PDSS=143; putamen BPND=1.532; caudate 
BPND=1.320; thalamus BPND=1.755; raphe BPND= 2.693), Parkinson’s patients without sleep 
dysfunction (62 year old male with disease duration of 4 years; PDSS=95; UPDRS-III score 
OFF medication of 17; putamen BPND=0.998; caudate BPND=0.732; thalamus BPND=1.282; 
raphe BPND=1.595) and Parkinson’s patients with sleep dysfunction (79 year old male with 
disease duration of 9 years; PDSS=51; UPDRS-III score OFF medication of 56; putamen 
BPND=0.828; caudate BPND=0.664; thalamus BPND=0.802; raphe BPND=1.457). Colour bar 
reflects range of [
11
C]DASB BPND intensity. 
Figure 4 Correlations between loss of [
11
C]DASB BPND and impaired sleep scores in patients 
with Parkinson’s disease. Lower scores on the PDSS correlated with lower [11C]DASB BPND 
in the caudate (P<0.001; r=0.77), putamen (P<0.001; r=0.84), ventral striatum (P<0.001; 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
16 
 
r=0.86), thalamus (P<0.001; r=0.79), hypothalamus (P<0.001; r=0.90) and raphe nuclei 
(P<0.001;  r=0.83). BPND = Non-displaceable Binding Potential; PDSS = Parkinson’s disease 
Sleep Scale.   
 
Tables 
Table 1 Clinical characteristics of patients with Parkinson’s disease and healthy controls 
 Healthy controls PD without sleep 
dysfunction 
PD with sleep 
dysfunction 
Number of subjects 12 14 14 
Age (years ± SD) 63.4 (±7.1) 67.4 (±4.2) 65.9 (±8.8) 
BMI (mean ± SD) 25.9 (±3.5) 25.5 (±3.6) 24.9 (±4.2) 
MMSE (mean ± SD) 29.4 (±0.7) 29.7 (±0.6) 28.9 (±1.9) 
BDI-II (mean ± SD) 3.1 (±2.6) 7.4 (±3.5) 8.4 (±3.1) 
HRSD (mean ± SD) 2.6 (±2.7) 6.2 (±2.6) 7.1 (±2.3) 
NMSS (Fatigue) No No No 
Disease duration (years ± SD) - 8.1 (±3.6) 8.7 (±3.1) 
H&Y OFF (mean ± SD) - 2.4 (±1.0) 3.1 (±0.6) 
UPDRS-III OFF (mean ± SD) - 38.6 (±11.7) 44.1 (±9.7) 
Daily LED (mean ± SD) - 792.1 (±760.5) 835.4 (±315.4) 
PDSS (mean ± SD) 114.0 (±3.8) 114.7 (±18.8) 58.2 (±17.2)*** 
Lower PDSS represents worse score (best = 150/ worst = 0).  PD = Parkinson’s disease; 
PDSS = Parkinson’s disease Sleep Scale; UPDRS-III = Unified Parkinson’s Disease Rating 
Scale part-III; H&Y = Hoehn & Yahr; BDI-II = Beck Depression Inventory-II; HRSD = 
Hamilton Rating Scale for Depression; NMSS = Non-Motor Symptom Scale; MMSE = Mini 
Mental State Examination. ***P<0.001. 
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Table 2 [
11C]DASB binding potential values in groups of Parkinson’s disease patients with 
and without sleep dysfunction and healthy controls 
P values are Bonferroni corrected for multiple-comparisons. NS* = Not Significant ANOVA. 
PD = Parkinson’s disease. PD control = Parkinson’s disease patients without sleep 
dysfunction; PD sleep = Parkinson’s disease patients with sleep dysfunction. 
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Highlights 
 
 Reduced PET [11C]DASB binding in Parkinson patients with sleep disturbances 
 PD with sleep disturbances show loss of serotonin in the striatum, raphe and hypothalamus 
 Loss of serotonin correlated with severity of sleep symptoms in PD patients 
 Serotonergic dysfunction could contribute to pathophysiology of sleep disturbances 
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